NCT00690768

Pars Plana Vitrectomy (PPV) Versus Preoperative Intravitreal Bevacizumab Plus PPV to Treat Diabetic Tractional Retinal Detachment (IBETRA)

Pars Plana Vitrectomy (PPV) Versus Preoperative Intravitreal Bevacizumab Plus PPV for Diabetic Tractional Retinal Detachment (IBETRA Study)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: University of Sao Paulo · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare the amount of intraoperative intraocular bleeding during 23-gauge pars plana vitrectomy (PPV) for diabetic traction retinal detachment (TRD) with and without preoperative intravitreal bevacizumab treatment.

Conditions

• Diabetic Retinopathy
• Retinal Detachment

Interventions

Type	Name	Description
DRUG	Bevacizumab	Intravitreal bevacizumab (1.5 mg; 0,06 ml) 1 week after baseline; pars plana vitrectomy 3 weeks after baseline
PROCEDURE	pars plana vitrectomy	pars plana vitrectomy 3 weeks after baseline

Timeline

• Start date: 2008-03-01
• Primary completion: 2008-05-01
• Completion: 2008-05-01
• First posted: 2008-06-05
• Last updated: 2008-06-05

Locations

1 site across 1 country: Brazil